We describe the use of bioactive peptides to drive liposomal drugs on target receptors overexpressed in cancer cells. A detailed description for several targeting liposomes derivatized with different peptides and thus able to target relevant receptors for cancer therapy is reported. Even if the development of peptide-targeted liposomes represents a great advance in the use of liposomal drugs for cancer therapy, many critical issues are still unsolved in the development of these innovative drug delivery systems. Advantages and drawbacks of the peptide-mediated active targeting are discussed.
No takes yet. Share an insight, caveat, or question.
Accardo et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: